Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

ROCHE DIAGNOSTICS CORP

Roche Diagnostics Corporation is the North American headquarters of Roche Diagnostics, a global leader in diagnostics... read more Featured Products: More products

Download Mobile App




Index Identifies Women at Risk for Rapid Bone Loss

By LabMedica International staff writers
Posted on 14 Jul 2016
Osteoporosis is often referred to as a "silent" disease because individuals who have it experience few noticeable symptoms and this progressive condition occurs when bones grow structurally weak and become more likely to fracture or break.

Biochemical markers of bone resorption and formation known as bone turnover markers (BTMs) have been available for clinical purposes for many years and in postmenopausal women, BTMs are correlated with histomorphometric indices of bone turnover, especially at sites of high remodeling. More...
Elevated BTM levels are also associated with faster rates of bone loss and increased fracture risk.

Scientists at the University of California, Los Angeles (CA, USA) and their colleagues conducted a study to determine whether resorption and formation markers can be combined to gauge net bone formation across the skeleton. The 685 women, who participated in the Study of Women's Health across the Nation, were between the ages of 42 and 52. The women were either premenopausal or in early perimenopause when they enrolled in the study, and all of the participants included in this analysis had their final menstrual period during the follow-up portion of the study.

The bone formation marker, serum osteocalcin (OC), was measured using the ELSA-OSTEO immunoradiometric assay as ng/mL (Cis-Bio International, Codolet, France). The bone resorption marker, urinary N-telopeptide (U-NTX), was measured using the Osteomark competitive inhibition enzyme immunoassay as nanomoles bone collagen equivalent [BCE] (Ostex International Inc, Seattle, WA, USA). Urinary creatinine was measured using the Cobas Mira autoanalyzer (Roche Diagnostics, Basel, Switzerland). Lumbar spine (LS) and femoral neck (FN) bone mineral densities BMDs were assessed by dual-energy x-ray absorptiometry.

The scientists found that the combined measurements of bone breakdown and bone formation in a Bone Balance Index to determine each individual's net bone balance before the final menstrual period. They found that this index was a stronger predictor of bone loss from two years before the final menstrual period to three to four years later, a time when bone density typically declines than a measurement of bone breakdown alone. Urinary N-telopeptide alone was not associated with either LS or FN BMD decline.

Albert Shieh, MD, one of the study authors said, “This novel approach to assessing an individual's bone health may help identify which women are at risk of losing vertebral bone mineral density across the menopause transition. Since markers of bone breakdown alone have limited utility in predicting bone loss at an individual level, better approaches are needed to ensure individuals at highest risk of rapid bone loss are identified as quickly as possible.” The study was published on June 23, 2016, in the Journal of Clinical Endocrinology & Metabolism.

Related Links:
University of California, Los Angeles
Cis-Bio International
Ostex International
Roche Diagnostics


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.